Interaction between the Adhesion Receptor, CD44, and the Oncogene Product, p185 HER2 , Promotes Human Ovarian Tumor Cell Activation*

In this study we have examined the interaction between CD44s (the standard form) and the p185 HER2 proto-oncogene in the ovarian carcinoma cell line. Surface biotinylation followed by wheat germ agglutinin column chromatography and anti-CD44-mediated immunoprecipitation indicate that both CD44s and p185 HER2 are expressed on the cell surface and most importantly, that these two molecules are physically linked to each other via interchain disulfide bonds. We have also determined that hyaluronic acid stimulates CD44s-associated p185 HER2 tyrosine kinase activity, leading to an increase in the ovarian carcinoma cell growth. After transfection of the ovarian carcinoma cell line with the adenovirus 5 E1A gene, which is known to repress p185 HER2 expression, we observed that both surface CD44s expression and CD44s-mediated cell adhesion to hyaluronic acid are significantly reduced in the transfectant cells compared with the control cells. These data suggest that down-regulation of p185 HER2 blocks CD44s expression and subsequent adhesion function. Our findings also indicate that the CD44s-p185 HER2 interaction is both functionally coupled and biosynthetically regulated. We believe that direct “cross-talk” between these two surface molecules (i.e. CD44s and the p185 HER2 ) may be one of the most important signaling events in human ovarian carcinoma development.

[1]  B. Toole,et al.  Hyaluronan-binding protein in endothelial cell morphogenesis , 1992, Journal of Cell Biology.

[2]  J. Niloff,et al.  Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. , 1993, Cancer research.

[3]  M. Sy,et al.  A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid , 1996, The Journal of experimental medicine.

[4]  L. Bourguignon,et al.  Ankyrin-binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function , 1994, The Journal of cell biology.

[5]  N. Maihle,et al.  Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions , 1996, Journal of virology.

[6]  P. Kincade,et al.  CD44 and its interaction with extracellular matrix. , 1993, Advances in immunology.

[7]  X. Chen,et al.  Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. , 1993, Journal of immunology.

[8]  William,et al.  Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. , 1988, The Journal of biological chemistry.

[9]  N Iida,et al.  The Cell Adhesion Molecule, GP116, Is a New CD44 Variant (ex14/v10) Involved in Hyaluronic Acid Binding and Endothelial Cell Proliferation* , 1996, The Journal of Biological Chemistry.

[10]  P. Herrlich,et al.  CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. , 1991, Cancer research.

[11]  M. Hung,et al.  Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[13]  L. Bourguignon,et al.  Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. , 1991, The Journal of biological chemistry.

[14]  S. Ethier,et al.  Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[15]  L. Liotta,et al.  Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development , 1989, Nature.

[16]  L. Bourguignon,et al.  Acylation of the lymphoma transmembrane glycoprotein, GP85, may be required for GP85-ankyrin interaction. , 1991, Journal of Biological Chemistry.

[17]  L. Bourguignon,et al.  The lymphoma transmembrane glycoprotein GP85 (CD44) is a novel guanine nucleotide-binding protein which regulates GP85 (CD44)-ankyrin interaction. , 1992, The Journal of biological chemistry.

[18]  M. Hung,et al.  Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. , 1993, Cancer research.

[19]  L. Bourguignon,et al.  New CD44 splice variants associated with human breast cancers , 1995, Journal of cellular physiology.

[20]  C. Underhill,et al.  CD44: the hyaluronan receptor. , 1992, Journal of cell science.

[21]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[22]  G. Nicolson,et al.  Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. , 1992, Oncogene.

[23]  L. Ellis,et al.  Expression of CD44R1 adhesion molecule in colon carcinomas and metastases , 1993, The Lancet.

[24]  Y. Yarden,et al.  Neu and its ligands: From an oncogene to neural factors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[25]  S. Jalkanen,et al.  Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin , 1992, The Journal of cell biology.

[26]  L. Bourguignon,et al.  Overexpression of CD44 in pl85(neu)-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell adhesion. , 1996, Oncogene.

[27]  M. Hung,et al.  Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. , 1992, Cancer letters.

[28]  B. Pauli,et al.  Tumor invasion: a consequence of destructive and compositional matrix alterations. , 1988, Human pathology.

[29]  L. Bourguignon,et al.  Lymphoma protein kinase C is associated with the transmembrane glycoprotein, GP85, and may function in GP85-ankyrin binding. , 1989, The Journal of biological chemistry.

[30]  L. Bourguignon Chapter 14 Interactions between the Membrane-Cytoskeleton and CD44 during Lymphocyte Signal Transduction and Cell Adhesion , 1996 .

[31]  J. Niloff,et al.  Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  H. Liao,et al.  N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. , 1995, Journal of immunology.

[33]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Piver,et al.  Epidemiology and etiology of ovarian cancer. , 1991, Seminars in oncology.